Thrombosis News and Research

Latest Thrombosis News and Research

Bristol-Myers Squibb, Pfizer announce FDA approval of Eliquis for DVT prophylaxis

Bristol-Myers Squibb Company and Pfizer Inc. today announced that the U.S. Food and Drug Administration approved a Supplemental New Drug Application (sNDA) for Eliquis (apixaban) for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in patients who have undergone hip or knee replacement surgery.

16 Mar 2014

Study finds higher readmission rates for same-day total joint replacement surgery

As the effectiveness of anesthesia, pain management and rehabilitation continues to improve, more orthopaedic procedures are being done on an outpatient basis. In a new research study presented today at the 2014 Annual Meeting of the American Academy of Orthopaedic Surgeons, same-day total joint replacement (TJR) patient outcomes were comparable to those of patients admitted to the hospital and staying at least one night following surgery.

14 Mar 2014

Positive margins have limited impact on RCC outcome

Positive vascular wall margins are not associated with systemic recurrence or cancer-specific survival in patients with nonmetastatic renal cell carcinoma with tumour thrombus, US research shows.

13 Mar 2014

Statins combined with conventional blood clot prevention therapies, reduce VTE risk by 48%

Statins have long been known to lower cholesterol and, more recently, to decrease the risk of deep vein thrombosis (blood clots) in healthy, non-surgical patients.

11 Mar 2014

Incyte Corporation publishes results of Phase III trial of ruxolitinib in patients with polycythemia vera

Incyte Corporation (Nasdaq: INCY) today announced that a pivotal Phase III trial of ruxolitinib compared to best available therapy in patients with polycythemia vera who are resistant to or intolerant of hydroxyurea has met its primary endpoint of achieving phlebotomy independence and reducing spleen size by 35 percent or more.

7 Mar 2014

Long-term risks of deep vein thrombosis

Deep vein thrombosis (DVT) often brings with it the risk of post-thrombotic syndrome (PTS), an under-recognized but serious complication that often causes long-term disability for patients. During March's DVT Awareness Month, the Society of Interventional Radiology wants to help patients and family members to better understand the long-term risks of DVT.

5 Mar 2014

Motesanib boosts carboplatin/paclitaxel efficacy in NSCLC

Adding motesanib to carboplatin/paclitaxel significantly improves overall survival in Asian patients with nonsquamous non-small-cell lung cancer compared with carboplatin/paclitaxel alone, researchers report.

27 Feb 2014

New optical device may help docs to diagnose blood coagulation status in near real time

Defective blood coagulation is one of the leading causes of preventable death in patients who have suffered trauma or undergone surgery. The body's natural defense against severe blood loss is the clotting process, in which platelets, plasma proteins, and other blood components interact to form a sticky, mesh-like structure.

26 Feb 2014

Mobile compression device just as effective as blood thinners in preventing DVT after joint surgery

Research from The Shiley Center for Orthopaedic Research and Education at Scripps Clinic could change how patients are treated to prevent blood clots after joint replacement surgery. A study published as the lead article in the current issue of the Journal of Bone and Joint Surgery determined that after lower extremity joint replacement surgery a mobile compression device was just as effective as blood thinners in preventing deep vein thrombosis (DVT), but without negative side effects including bleeding complications.

15 Feb 2014

Women's blood clot risk remains elevated for at least 12 weeks after delivering a baby, says study

Women's blood clot risk remains elevated for at least 12 weeks after delivering a baby - twice as long as previously recognized, according to a large study presented at the American Stroke Association's International Stroke Conference 2014.

14 Feb 2014

FDA accepts Regado Biosciences' IND application for REG2

Regado Biosciences, Inc., a biopharmaceutical company focused on the late-stage clinical development of its first-in-class, actively controllable antithrombotic drug system, REG1, today announced that the United States Food and Drug Administration has accepted the company's investigational new drug (IND) application for REG2. Regado previously completed a single escalating-dose Phase 1 clinical trial of REG2 and plans to conduct additional clinical testing in sub-acute venous thrombosis indications in the future.

13 Feb 2014

Jazz Pharmaceuticals' Versacloz now commercially available in the U.S. for schizophrenia

Jazz Pharmaceuticals plc today announced U.S. commercial availability of Versacloz (clozapine, USP) oral suspension, the first and only oral suspension clozapine for severely ill treatment-resistant schizophrenia patients or those at risk of recurrent suicidal behavior with schizophrenia or schizoaffective disorder.

11 Feb 2014

Chest radiography highly predictive of pulmonary hypertension

Chest radiography is very accurate for predicting pulmonary hypertension, report researchers.

3 Feb 2014

Research helps identify stroke patients at risk for mortality and treatments to reduce death rate

For patients who have experienced a large stroke that cuts off blood supply to a large part of the brain, the use of standardized medical management protocol and surgery to decompress swelling can improve life expectancy, Mayo Clinic researchers found in a recent study.

28 Jan 2014

Use of standardized medical management protocol and surgery can improve life expectancy

28 Jan 2014

Bristol-Myers Squibb fourth quarter 2013 revenues increase 6% to $4.4 billion

Bristol-Myers Squibb Company today reported results for the fourth quarter and full year of 2013. The fourth quarter was highlighted by the company's announcement to sell its diabetes business as part of the continued evolution of its successful BioPharma strategy to a specialty care model. The company achieved important regulatory milestones in the quarter for Eliquis in the U.S., daclatasvir/asunaprevir in Japan, daclatasvir in Europe and Farxiga in the U.S. In addition, the company provided financial guidance for 2014.

24 Jan 2014

Clinical rule stratifies CAP patients’ cardiac risk

Researchers have generated and validated a clinical rule that accurately stratifies patients hospitalized for community acquired pneumonia according to their risk for cardiac complications.

20 Jan 2014

Ceram-lead project to develop new biomaterials and new arterial stents awarded Euro 5.874M by the European Union

As co-ordinator of the European project ‘ReBioStent’, Ceram, the international materials technology company, is pleased to announce that the project, to develop new biomaterials and new arterial stents, has been awarded Euro 5.874M by the European Union.

20 Jan 2014

ARIAD Pharmaceuticals' Iclusig now commercially available to patients in the U.S.

ARIAD Pharmaceuticals, Inc. today announced the commercial availability of Iclusig (ponatinib) for adult patients with refractory chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia in the United States. ARIAD has begun shipping Iclusig to Biologics, Inc., its exclusive specialty pharmacy, which is now filling prescriptions from physicians and distributing the cancer medicine to patients.

18 Jan 2014

First commercial implant of Elixir's DESolve Novolimus Eluting Coronary Scaffold performed in Germany

Marking a milestone in the evolution of fully-bioresorbable drug-eluting scaffolds for interventional cardiology, the first commercial implant of Elixir Medical's CE Mark-approved DESolve Novolimus Eluting Coronary Scaffold was performed in Germany by Professor Dr. med. Holger Nef, Head of the Cardiac Catheterization Laboratory, University Hospital Giessen, Giessen, Germany.

15 Jan 2014

Thrombosis News and Research

Latest Thrombosis News and Research

Bristol-Myers Squibb, Pfizer announce FDA approval of Eliquis for DVT prophylaxis

Study finds higher readmission rates for same-day total joint replacement surgery

Positive margins have limited impact on RCC outcome

Statins combined with conventional blood clot prevention therapies, reduce VTE risk by 48%

Incyte Corporation publishes results of Phase III trial of ruxolitinib in patients with polycythemia vera

Long-term risks of deep vein thrombosis

Motesanib boosts carboplatin/paclitaxel efficacy in NSCLC

New optical device may help docs to diagnose blood coagulation status in near real time

Mobile compression device just as effective as blood thinners in preventing DVT after joint surgery

Women's blood clot risk remains elevated for at least 12 weeks after delivering a baby, says study

FDA accepts Regado Biosciences' IND application for REG2

Jazz Pharmaceuticals' Versacloz now commercially available in the U.S. for schizophrenia

Chest radiography highly predictive of pulmonary hypertension

Research helps identify stroke patients at risk for mortality and treatments to reduce death rate

Use of standardized medical management protocol and surgery can improve life expectancy

Bristol-Myers Squibb fourth quarter 2013 revenues increase 6% to $4.4 billion

Clinical rule stratifies CAP patients’ cardiac risk

Ceram-lead project to develop new biomaterials and new arterial stents awarded Euro 5.874M by the European Union

ARIAD Pharmaceuticals' Iclusig now commercially available to patients in the U.S.

First commercial implant of Elixir's DESolve Novolimus Eluting Coronary Scaffold performed in Germany

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Thrombosis News and Research

Latest Thrombosis News and Research

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Newsletters you may be interested in